Pfizer CentreOne expands contract manufacturing in Japan

By Melissa Fassbender

- Last updated on GMT

Pfizer CentreOne's new site in Japan, Nagoya. (Image: Pfizer CentreOne)
Pfizer CentreOne's new site in Japan, Nagoya. (Image: Pfizer CentreOne)

Related tags Manufacturing Pharmacology Japan

Pfizer’s contract development and manufacturing organization (CDMO) is now offering services in Nagoya, Japan.

The new site will manufacture highly active compounds, immunosuppresive drugs, sensitizing agents, and controlled drugs. Dosage forms available include high and multiple doses, combination products, multiple release and fixed dose.

According to the CDMO, the facility will also provide “gateway services” into Japan, including inspection, packaging, and testing for highly potent oral solid drugs and sterile injectables made by the company outside the country.

The company will also provide inspection and packaging services for drugs manufactured at the Japan facility and will also offer services such as cold-chain handling and market testing for release to the Japanese market.

Earlier this year, Pfizer CentreOne also expanded its fill-finish and highly potent solid oral dose service offerings at two of its contract manufacturing facilities in the US and Ireland. Pete Stevenson, Pfizer CentreOne vice president and general manager told us at the time that the company would be growing​ to meet the needs of its biopharmaceutical partners.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us

Webinars

Headlines